Hoʻokaʻawale i ka lymphoma B-cell nui (DLBCL), NOS, subtype GCB, lymphoma-01 pūnaewele puni honua mua.

I Kekemapa 2019, ua hoʻomaka ʻo Mr. Wang, he kumu mai ka ʻĀkau Hikina Kina, e ʻike i ka ʻeha poʻo. Ma ka lā 19 o Dekemaba, 2019, ua hōʻike ʻia nā hoʻokolohua diagnostic i kēia: Ua hōʻike ʻo PET-CT i kahi aniani ākea me ka hoʻonui nui ʻana o ka FDG metabolism ma ka ʻaoʻao hema hema a me ka corpus callosum kuli wahi (ma kahi o 3.4 * 1.9 cm, SUVmax=34.4). ʻO ka biopsy a me ka immunohistochemistry i hōʻoia i ka diffuse nui B-cell lymphoma (DLBCL, NOS, GCB subtype), me kahi immunophenotype e hōʻike ana iā Ki67 (50%+), CD19 (+), CD20 (+), PAX5 (+), CD79 (+), MUM1(+), BCL(+), CD10(-/+), CD2(ʻuʻuku+). Ua hōʻike ʻia ka nānā ʻana o ka wai cerebrospinal i ka 6% o nā pūnaewele lymphoid ʻaʻole me ka ʻokoʻa morphological. ʻO ka maʻi maʻi ʻo ia ka lymphoma ʻōnaehana waena waena (DLBCL, GCB subtype).

Ma hope o ka noiʻi ʻana i nā koho lapaʻau ma ka pūnaewele, ua aʻo ʻo Mr. Wang e pili ana i ka hiki ke immunotherapy o ka Halemai Lu Dao Pei a ʻimi koke i ko lākou ʻike. Ma hope o ka hoʻokolokolo kino kino a me ka nānā pono ʻana e ka hui loea o ka haukapila, ua hoʻoholo ʻia e komo ʻo Mr. Ua loaʻa iā ia ka autologous CD19 CAR-T cell infusion ma ʻApelila 24, 2023. Ma Iulai 30, 2023, ua loiloi ʻia ua loaʻa iā ia ke kala piha (CR) a ua hoʻi i ke ola maʻamau.